Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Neuronetics, Inc.NASDAQ: STIM

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $18.3M rose 12.7% year over year, behind the +141.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 8.8% from the prior quarter. Over 3 fiscal years it compounded at +70.6% a year.

Context

  • Cost of revenue amounted to 51.5% of revenue in FY2025, up 23.8 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +12.7% toward the trailing-twelve-month pace of +141.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.3M-8.8% QoQ
Last fiscal yearDec 2025
$76.85M+270.7% YoY
LTMMar 2026
$78.91M+141.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.7%——
1 year+270.7%——
3-year CAGR+70.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
76.85M USD
Year-over-year change
+270.7%
4-year CAGR
+60.3%

Cost of Revenue vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +141.8% is the 2nd highest of 7, against a peer median of +7.9%.
  • Cost of revenue amounts to 52.0% of revenue for STIM, versus a peer median of 51.7%.
STIM Competitors
Cost of Revenue for STIM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATLNAtlantic International Corp.LTM Dec 2025$389.89M USD-1.4%+0.2%89.4%
STIMNeuronetics, Inc.LTM Mar 2026$78.91M USD+141.8%+70.6%52.0%
OSUROraSure Technologies, Inc.LTM Mar 2026$66.66M USD-28.2%-34.6%59.0%
PREPrenetics Global LimitedLTM Mar 2026$47.41M USD+110.1%+65.9%41.7%
OABIOmniAb, Inc.LTM Mar 2026$18.66M USD——64.5%
CDXSCodexis, Inc.LTM Mar 2026$12.54M USD-11.5%-37.4%16.1%
NYXHNyxoah S.A.LTM Mar 2026€8.43M EUR+460.5%+47.5%51.7%
PROFProfound Medical Corp.LTM Mar 2026$5.46M USD+17.1%+9.4%28.9%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$2.63M USD——426.2%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$0 USD—-14.4%0.0%
Peer median (excluding STIM) —+7.9%+0.2%51.7%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M65.21M71.35M74.89M149.16M
Cost of Revenue11.65M15.48M19.64M20.73M76.85M
Gross Profit43.66M49.72M51.71M54.16M72.31M
Gross Margin78.9%76.3%72.5%72.3%48.5%
Research & Development7.92M9.34M9.52M12.77M6.58M
Selling, General & Admin63.3M75.5M72.74M75.95M97.16M
Operating Expenses71.22M84.83M82.26M88.72M103.74M
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
EBITDA(26.81M)(31.96M)(22.76M)(34.37M)(27.12M)
EBITDA Margin-48.5%-49.0%-31.9%-45.9%-18.2%
Operating Income(27.56M)(35.11M)(30.55M)(34.56M)(31.44M)
Operating Margin-49.8%-53.8%-42.8%-46.2%-21.1%
Interest Income0024K00
Interest Expense3.3M3.6M5.42M7.29M8.42M
Other Income / Expenses(3.61M)(2.1M)365K(9.18M)(7.56M)
Income Before Tax(31.17M)(37.21M)(30.19M)(43.74M)(39M)
Pre-Tax Margin-56.4%-57.1%-42.3%-58.4%-26.1%
Income Tax Expense00(24K)(14K)0
Net Income(31.19M)(37.16M)(30.19M)(43.71M)(39M)
Net Margin-56.4%-57.0%-42.3%-58.4%-26.1%
EPS (Basic)(1.22)(1.38)(1.05)(1.38)(0.59)
EPS (Diluted)(1.22)(1.38)(1.05)(1.38)(0.59)
Weighted Avg Shares25.48M26.9M28.66M31.73M65.95M
Weighted Avg Shares (Diluted)25.48M26.9M28.66M31.73M65.95M

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.